GRI Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in La Jolla, California, focused on developing immune cell modulators for inflammatory, fibrotic, and autoimmune diseases. Its lead candidate, GRI-0621, is an oral RARβ/γ-selective agonist designed to inhibit type 1 natural killer T (NKT) cells and is being evaluated as a once-daily treatment for idiopathic pulmonary fibrosis, a progressive and life-threatening lung disease with substantial unmet need.
The company's broader pipeline includes type 2 diverse NKT (dNKT) agonist candidates targeting systemic lupus erythematosus and a proprietary library of more than 500 compounds. Investors follow GRI primarily for clinical catalysts around GRI-0621, which has generated encouraging Phase 2a biomarker, safety, and lung-function data, as well as U.S. FDA Orphan Drug Designation in IPF. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, GRI shares advanced approximately 23%, recovering from a closing price near $1.38 in mid-October to $1.70 by mid-November. The move marked a rebound from the lower end of the stock's recent trading range, which bottomed around $1.36, and reflected a meaningful improvement in sentiment rather than a single corporate announcement.
The quarterly picture is more mixed. Measured across the trailing three months, the stock ended roughly flat versus its mid-August level, but that headline obscures sharp swings. GRI spiked to an intra-quarter high near $2.88 in early September around the European Respiratory Society Congress, then gave back those gains through September and October before stabilizing and recovering into November. The result is a volatile, range-bound quarter with a net positive bias in the most recent weeks.
Several factors converged to support the 30-day rebound. A key catalyst was positive Phase 3 data from Bristol Myers Squibb (BMY)'s ALOFT-IPF trial of admilparant, which validated the broader IPF development space and prompted H.C. Wainwright to reiterate a Buy rating on GRI Bio, pointing to the read-through for the company's lead program. That sector-level validation helped reverse the stock's October slide.
Company-specific news also contributed. On November 4, GRI Bio held its 2026 annual meeting, where stockholders elected two Class III directors, ratified its auditor, and approved an amendment to its 2018 Equity Incentive Plan that added 546,529 shares and extended an evergreen provision. The company subsequently published its third-quarter 2026 results in mid-November. Combined with an already oversold technical setup, these developments supported the move higher, though the stock's low float and thin liquidity amplified the percentage swings.
The broader quarterly narrative has been defined by clinical data and regulatory milestones. Through late 2025 and early 2026, GRI Bio reported positive Phase 2a topline, biomarker, and gene-expression data for GRI-0621, and secured FDA Orphan Drug Designation in IPF. Data presentations at the ERS 2026 Congress in September drove a sharp but short-lived rally before profit-taking and general pressure on micro-cap biotech names pulled shares back.
Broader IPF sector dynamics, including Bristol Myers Squibb (BMY)'s Phase 3 results, also shaped the quarter. While the stock ended the period near where it began, the cadence of clinical and regulatory news kept volatility elevated and left GRI positioned for event-driven moves around future data readouts and financing decisions.
Looking ahead, the key drivers for GRI are clinical and financial. Investors should monitor the next steps in the GRI-0621 development program, including regulatory feedback and the company's plans for advancing toward later-stage IPF studies, as well as progress on its lupus-focused pipeline. Upcoming quarterly earnings and guidance updates will also be important, given that GRI Bio generates no product revenue and relies on disciplined capital management, with cash runway a persistent consideration for a clinical-stage company.
Sector catalysts matter too. Continued positive IPF trial data from larger developers could sustain investor interest in the space, while broader risk appetite for micro-cap biotech names will continue to influence short-term price action. As with any early-stage biotech, outcomes depend on clinical success, regulatory decisions, and the company's ability to fund operations. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge potential momentum shifts.
In my own trading, I've found Tickeron’s Trending AI Robots page useful for scanning automated strategies. It curates top-performing bots from a broader library spanning hundreds of bots trading thousands of tickers, each differing in strategy, timeframe, and performance metrics. This approach helps align tools with personal risk tolerance and holding periods when researching names like GRI Bio.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Indicator for GRI moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 53 similar instances when the indicator left oversold territory. In 49 of the 53 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +31.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where GRI advanced for three days, in 184 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GRI as a result. In 75 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for GRI turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 36 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
GRI moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
GRI broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GRI entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.400) is normal, around the industry mean (3.592). P/E Ratio (-0.664) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.042) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. GRI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology